Trials / Completed
CompletedNCT00248313
Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus
A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporin Dose Reduction With Cyclosporin Elimination in de Novo Renal Allograft Recipients Receiving Rapamune
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 470 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving induction therapy with cyclosporin (CsA, Neoral) and Rapamune® followed by CsA dose reduction and concentration-controlled Rapamune® versus induction with CsA and Rapamune® followed by discontinuation of CsA and concentration-controlled Rapamune®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapamune® |
Timeline
- Start date
- 2000-07-01
- Completion
- 2007-10-01
- First posted
- 2005-11-03
- Last updated
- 2010-03-10
Source: ClinicalTrials.gov record NCT00248313. Inclusion in this directory is not an endorsement.